Media coverage about Stellar Biotechnologies (NASDAQ:SBOT) has been trending somewhat positive recently, Accern reports. The research group identifies negative and positive news coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Stellar Biotechnologies earned a news sentiment score of 0.05 on Accern’s scale. Accern also assigned press coverage about the biotechnology company an impact score of 46.6870086932939 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near term.

Shares of Stellar Biotechnologies (NASDAQ:SBOT) traded down 0.78% during mid-day trading on Friday, hitting $1.22. The stock had a trading volume of 34,871 shares. The firm has a 50 day moving average of $1.17 and a 200 day moving average of $1.25. Stellar Biotechnologies has a one year low of $1.05 and a one year high of $3.00. The stock’s market cap is $12.83 million.

Stellar Biotechnologies (NASDAQ:SBOT) last released its quarterly earnings data on Wednesday, August 9th. The biotechnology company reported ($0.12) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.12). The company had revenue of $0.02 million for the quarter, compared to the consensus estimate of $0.34 million. Stellar Biotechnologies had a negative return on equity of 49.68% and a negative net margin of 1,025.65%. On average, analysts forecast that Stellar Biotechnologies will post ($0.47) earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: This piece of content was published by Watch List News and is the sole property of of Watch List News. If you are accessing this piece of content on another site, it was illegally copied and republished in violation of U.S. and international trademark & copyright laws. The original version of this piece of content can be accessed at

About Stellar Biotechnologies

Stellar Biotechnologies, Inc is a biotechnology company. The Company is engaged in the aquaculture, research and development, manufacture and commercialization of Keyhole Limpet Hemocyanin (KLH). KLH is an immune-stimulating protein. KLH can be used as an active pharmaceutical ingredient (API) and combined with a disease-targeting agent to create immunotherapies for the treatment of a range of diseases.

Insider Buying and Selling by Quarter for Stellar Biotechnologies (NASDAQ:SBOT)

Receive News & Ratings for Stellar Biotechnologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stellar Biotechnologies Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.